España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Comments
Close menu
Loading...
Roivant Sciences
ROIV
NASDAQ
Watchlist
Leave a Comment
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$11.09
-0.04
-0.36%
Last update: 9:25 AM
15 minutes delayed
Get Report
Comment
Roivant Sciences (ROIV) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Roivant Sciences (NASDAQ:ROIV) Stock
Roivant Sciences Stock (NASDAQ: ROIV)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, July 10, 2024
Piper Sandler Maintains Overweight on Roivant...
Benzinga Newsdesk
Tuesday, June 18, 2024
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on Ro...
Benzinga Newsdesk
Friday, May 31, 2024
The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk
Thursday, May 30, 2024
Roivant Sciences Q4 2024 GAAP EPS $(0.19) Bea...
Benzinga Newsdesk
Wednesday, May 22, 2024
Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On?
Vandana Singh
Thursday, April 25, 2024
Roivant And Kinevant Sciences Complete Enroll...
Benzinga Newsdesk
Monday, April 22, 2024
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Roivant...
Benzinga Newsdesk
Wednesday, April 03, 2024
Goldman Sachs Maintains Buy on Roivant Scienc...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Roivant ...
Benzinga Newsdesk
Deutsche Bank Maintains Buy on Roivant Scienc...
Benzinga Newsdesk
Tuesday, April 02, 2024
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study
Vandana Singh
Roivant Sciences shares are trading higher af...
Benzinga Newsdesk
Roivant Sciences Reveals Board Authorization ...
Benzinga Newsdesk
Roivant Announces Positive NEPTUNE Study Resu...
Benzinga Newsdesk
Friday, March 29, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Wednesday, March 27, 2024
Roivant Sciences shares are trading higher af...
Benzinga Newsdesk
Tuesday, March 26, 2024
Roivant Sciences To Replace Sunrun In S&P Mid...
Benzinga Newsdesk
Monday, March 25, 2024
Where Roivant Sciences Stands With Analysts
Benzinga Insights
Truist Securities Reiterates Buy on Roivant S...
Benzinga Newsdesk
Monday, February 19, 2024
5 Value Stocks In The Healthcare Sector
Benzinga Insights
Thursday, February 15, 2024
Wolfe Research Initiates Coverage On Roivant ...
Benzinga Newsdesk
Wednesday, February 14, 2024
The Analyst Landscape: 4 Takes On Roivant Sciences
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Roivant ...
Benzinga Newsdesk
Tuesday, February 13, 2024
Roivant Sciences Q3 2024 Adj EPS $(0.21) Beat...
Benzinga Newsdesk
Earnings Scheduled For February 13, 2024
Benzinga Insights
Monday, February 12, 2024
Roivant Sciences Earnings Preview
Benzinga Insights
Wednesday, January 10, 2024
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Vandana Singh
Friday, January 05, 2024
Piper Sandler Initiates Coverage On Roivant S...
Benzinga Newsdesk
Tuesday, January 02, 2024
Assessing Roivant Sciences: Insights From 5 Financial Analysts
Benzinga Insights
B of A Securities Maintains Neutral on Roivan...
Benzinga Newsdesk
Thursday, December 21, 2023
Roivant shares are trading higher after Immun...
Benzinga Newsdesk
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
Vandana Singh
Wednesday, December 20, 2023
Immunovant Says Results From Initial Cohort O...
Benzinga Newsdesk
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Avi Kapoor
Tuesday, December 12, 2023
Analyst Ratings for Roivant Sciences
Benzinga Insights
Deutsche Bank Initiates Coverage On Roivant S...
Benzinga Newsdesk
Tuesday, November 28, 2023
Roivant Announces Positive IMVT-1402 Initial ...
Benzinga Newsdesk
Monday, November 27, 2023
Why Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today?
Vandana Singh
Roivant Sciences shares are trading lower aft...
Benzinga Newsdesk
Roivant And Priovant's Phase 2 Study Of Oral ...
Benzinga Newsdesk
Wednesday, November 15, 2023
Guggenheim Maintains Buy on Roivant Sciences,...
Benzinga Newsdesk
Tuesday, November 14, 2023
8 Analysts Have This to Say About Roivant Sciences
Benzinga Insights
JP Morgan Maintains Overweight on Roivant Sci...
Benzinga Newsdesk
Monday, November 13, 2023
Roivant Looks Forward To Announcing Additiona...
Benzinga Newsdesk
Roivant Sciences Q2 EPS $(0.40) Vs. $(0.42) L...
Benzinga Newsdesk
Earnings Scheduled For November 13, 2023
Benzinga Insights
Friday, November 10, 2023
Roivant Sciences Earnings Preview
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch